solid partli off-set fx margin
net dbt
good top-lin start margin fall bit short
pre-announce link holx revenu yoy
constant currenc cc vs guid upsid driven strength
core breast health diagnost busi well better expect blood
screen organ basi ex blood sale increas yoy ad
gm declin yoy estim opm declin yoy
vs estim deal account increment opex ep
vs estim grew yoy due part lower share count
guidanc rais modest core biz trend encourag
management updat guid yoy cc revenu growth
previou rang exclud fx
increment headwind vs prior guid recent acquisit faxitron
focal expect contribut quarter impli
yoy pro forma organ revenu growth ep guid
rais midpt in-lin consensu share count lower
see sale street due
part season ep also street overal
good start core growth molecular diagnost mdx core
growth breast imag ou growth comp get tougher
updat guid suggest ep upsid may limit final cynosur cyno continu
fall short management see return growth still forecast declin
reiter neutral rate
adjust estim rais po reiter neutral rate
lower sale chiefli due fx
ep estimate drop lower margin ep higher
higher core growth lower share count assumpt due stronger trend
breast mdx well peer multipl expans rais po
po base ep estimate ahead
histor averag in-lin diagnost peer
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi diagnost
busi deliv solid perform
especi ou market help
partial off-set issu relat
cynosur busi acquir continu
reserv cynosur
lack visibl concern although
po base approxim calendar ep estim impli
ev/ebitda ahead three-year histor averag in-
line compani diagnost med-tech peer multipl believ
justifi given strength breast molecular diagnost
upsid risk po better-than-expect synergi cynosur
acquisit unreal benefit chang tax code faster growth
core diagnost mammographi gynecolog surgeri end market
downsid risk po cynosur competit pressur slower uptak
reimburs new product unfavor chang clinic practic guidelin
manag departur regulatori risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
